ENGENE HOLDINGS INC(ENGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ENGN ENGENE HOLDINGS INC

Pre-Mkt 02-20 07:05:03 EST

10.62

+0.56

+5.57%

盘前9.80

-0.82-7.72%

06:43 EST

High10.69	Low9.96	Vol190.25K
Open10.02	D1 Closing10.06	Amplitude7.21%
Mkt Cap711.38M	Tradable Cap396.47M	Total Shares66.98M
T/O2.00M	T/O Rate0.51%	Tradable Shares37.33M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ENGN","market":"US","secType":"STK","nameCN":"ENGENE HOLDINGS INC","latestPrice":10.62,"timestamp":1771534800000,"preClose":10.06,"halted":0,"volume":190253,"hourTrading":{"tag":"盘前","latestPrice":9.8,"preClose":10.62,"latestTime":"06:43 EST","volume":410,"amount":4055.7999499999996,"timestamp":1771587802711,"change":-0.82,"changeRate":-0.077213,"amplitude":0.025424},"delay":0,"changeRate":0.05566600397614301,"floatShares":37332800,"shares":66984661,"eps":-2.294663,"marketStatus":"Pre-Mkt","change":0.56,"latestTime":"02-20 07:05:03 EST","open":10.02,"high":10.685,"low":9.96,"amount":1996746.9004070002,"amplitude":0.072068,"askPrice":10.5,"askSize":5,"bidPrice":9.79,"bidSize":7,"shortable":3,"etf":0,"ttmEps":-2.294663,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1771597800000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":10.62,"preHourTrading":{"tag":"盘前","latestPrice":9.8,"preClose":10.62,"latestTime":"06:43 EST","volume":410,"amount":4055.7999499999996,"timestamp":1771587802711,"change":-0.82,"changeRate":-0.077213,"amplitude":0.025424},"postHourTrading":{"tag":"盘后","latestPrice":10.5,"preClose":10.62,"latestTime":"17:17 EST","volume":503,"amount":5316.09,"timestamp":1771539472648,"change":-0.12,"changeRate":-0.011299,"amplitude":0.011299},"volumeRatio":1.315983149419464},"requestUrl":"/m/hq/s/ENGN","defaultTab":"news","newsList":[{"id":"2612688172","title":"EnGene Files $400 Million Mixed Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2612688172","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612688172?lang=en_us&edition=fundamental","pubTime":"2026-02-20 16:52","pubTimestamp":1771577547,"startTime":"0","endTime":"0","summary":"EnGene  filed a shelf registration statement late Thursday for the potential sale of up to $400 million in securities, to be offered from time to time.The filing covers the sale of common shares, preferred shares, debt securities, subscription receipts, warrants and units.The company aims to use the proceeds from the offering for general corporate purposes","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2612395462","title":"BRIEF-Engene Holdings Files For Mixed Shelf Of Upto $400 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2612395462","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612395462?lang=en_us&edition=fundamental","pubTime":"2026-02-20 06:26","pubTimestamp":1771539991,"startTime":"0","endTime":"0","summary":"BRIEF-Engene Holdings Files For Mixed Shelf Of Upto $400 MillionFeb 19  - enGene Holdings Inc ENGN.O:ENGENE HOLDINGS INC - FILES FOR MIXED SHELF OF UPTO $400 MILLION - SEC FILING - SEC FILINGSource text: [ID:n0001193125-26-059479]Further company coverage: ENGN.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nFWN3ZF1GV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2612235479","title":"enGene files $400M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2612235479","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612235479?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:36","pubTimestamp":1771536968,"startTime":"0","endTime":"0","summary":"16:31 EST enGene (ENGN) files $400M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking fi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/engene-files-400m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/engene-files-400m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2612358342","title":"enGene Holdings Inc - Files for Mixed Shelf of Upto $400 Mln - SEC Filing - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2612358342","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612358342?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:28","pubTimestamp":1771536505,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nFWN3ZF1GV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2608645763","title":"enGene Holdings nimmt am Guggenheim Emerging Outlook: Biotech Summit teil","url":"https://stock-news.laohu8.com/highlight/detail?id=2608645763","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608645763?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:01","pubTimestamp":1770210115,"startTime":"0","endTime":"0","summary":"enGene Holdings Inc. wird am Mittwoch, den 11. Februar 2026, um 14:30 Uhr  an einem Fireside-Chat im Rahmen des Guggenheim Emerging Outlook: Biotech Summit 2026 teilnehmen.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published the original content used to generate this news brief via Business Wire  on February 04, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL78sDKh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2607488610","title":"Jefferies Initiates Coverage on enGene With Buy Rating, $28 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2607488610","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607488610?lang=en_us&edition=fundamental","pubTime":"2026-01-30 20:29","pubTimestamp":1769776192,"startTime":"0","endTime":"0","summary":"enGene Holdings (ENGN) has an average rating of Buy and mean price target of $31.85, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2607016330","title":"enGene initiated with a Buy at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2607016330","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607016330?lang=en_us&edition=fundamental","pubTime":"2026-01-30 18:00","pubTimestamp":1769767228,"startTime":"0","endTime":"0","summary":"Jefferies initiated coverage of enGene (ENGN) with a Buy rating and $28 price target The company is running a pivotal high-risk non-muscle invasive...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/engene-initiated-with-a-buy-at-jefferies-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/engene-initiated-with-a-buy-at-jefferies-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2605438059","title":"enGene Holdings Issues 2026 Warrants to Purchase Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2605438059","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605438059?lang=en_us&edition=fundamental","pubTime":"2026-01-22 05:07","pubTimestamp":1769029628,"startTime":"0","endTime":"0","summary":"enGene Holdings Inc. announced the issuance of 2026 Closing Date Warrants to purchase common shares. The warrants were issued in connection with a loan agreement, with an aggregate of 40,850 warrants issued to lenders on the closing date. Each warrant has an exercise price of $9.18 per share and is exercisable for seven years from issuance. The total maximum number of 2026 Warrants that may be issued under the agreement is 204,248, representing 1.50% of the total loan commitment amount divided by the exercise price. The transaction was conducted as an unregistered sale of equity securities pursuant to Section 4 of the Securities Act of 1933.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published the original cont","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL4XkLfq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2605424051","title":"enGene Holdings  - Secures up to $100 Mln for Detalimogene Development & Commercialization for Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2605424051","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605424051?lang=en_us&edition=fundamental","pubTime":"2026-01-21 06:37","pubTimestamp":1768948649,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nFWN3YL1CD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2605142473","title":"enGene Announces Expanded $125 Million Debt Facility With Hercules Capital, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2605142473","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605142473?lang=en_us&edition=fundamental","pubTime":"2026-01-21 06:37","pubTimestamp":1768948649,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nFWN3YL1CD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2605142413","title":"enGene Secures Expanded $125 Million Debt Facility from Hercules Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2605142413","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605142413?lang=en_us&edition=fundamental","pubTime":"2026-01-21 06:35","pubTimestamp":1768948516,"startTime":"0","endTime":"0","summary":"enGene Holdings Inc., a clinical-stage genetic medicines company, has announced an amendment to its existing loan and security agreement with Hercules Capital, Inc., increasing its debt facility to up to $125 million. Under the revised terms, enGene has received an initial $25 million to refinance existing debt, with access to three additional tranches totaling $75 million contingent on achieving certain clinical, regulatory, and commercial milestones. An additional tranche of up to $25 million may be made available at Hercules' discretion. The funding strengthens enGene’s balance sheet as it prepares for a Biologics License Application to the FDA for detalimogene voraplasmid in the second half of 2026 and a potential commercial launch in 2027. All outstanding principal and accrued interest are to be repaid by January 1, 2030, unless extended under the loan agreement terms.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL8gJ3Yb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","HTGC","BK4139","BK4135"],"gpt_icon":0},{"id":"2593530564","title":"EnGene Fiscal 2025 Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2593530564","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593530564?lang=en_us&edition=fundamental","pubTime":"2025-12-23 06:12","pubTimestamp":1766441578,"startTime":"0","endTime":"0","summary":"EnGene  reported a fiscal 2025 net loss late Monday of $2.29 per diluted share, widening from a loss of $1.46 a year earlier.Analysts polled by FactSet expected a loss of $2.10.Cash, cash equivalents and marketable securities totaling $342.4 million, including proceeds from a November public offering, are expected to fund operations into the second half of 2028.Following discussions with the US Food and Drug Administration on its statistical analysis plan and the accumulation of 12-month complete response data, enGene said it expects to provide a data update on the Legend trial's pivotal cohort in the second half of 2026.The company also said it plans to submit a biologics license application for detalimogene for bacillus calmette-guerin unresponsive non-muscle-invasive bladder cancer in H2 2026.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2593458566","title":"enGene Holdings Q4 EPS $(0.73) Misses $(0.57) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2593458566","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593458566?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:04","pubTimestamp":1766437483,"startTime":"0","endTime":"0","summary":"enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.57) by 28.3 percent. This is a 114.71 percent decrease over losses of $(0.34) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/12/49549264/engene-holdings-q4-eps-0-73-misses-0-57-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"enGene Holdings Q4 EPS $(0.73) Misses $(0.57) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2593583784","title":"enGene reports FY net loss of USD 117.3 million, more than double year-on-year","url":"https://stock-news.laohu8.com/highlight/detail?id=2593583784","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593583784?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:03","pubTimestamp":1766437403,"startTime":"0","endTime":"0","summary":"enGene Holdings Inc. reported its full year  financial results for the period ended October 31, 2025. The company posted a net loss of USD 117.3 million for the year. Total operating expenses for the period were USD 123.2 million, including research and development expenses of USD 94.5 million and general and administrative expenses of USD 28.7 million. Net loss per share, basic and diluted, was USD 2.29. As of October 31, 2025, enGene Holdings Inc. reported cash, cash equivalents, and marketable securities of USD 202.3 million. The weighted-average number of common shares outstanding, basic and diluted, was 51,119,479 for the year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published the original content used ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL7QrwSq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2593458607","title":"enGene Holdings Inc - Cash and Marketable Securities Plus Proceeds From Nov Financing Expected to Provide Cash Runway Into 2H 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2593458607","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593458607?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:03","pubTimestamp":1766437380,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUAKX7C8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2593583224","title":"Press Release: enGene Reports Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2593583224","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593583224?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:03","pubTimestamp":1766437380,"startTime":"0","endTime":"0","summary":"Completed enrollment in LEGEND's pivotal cohort with 125 patients in high-risk, BCG-unresponsive NMIBC with carcinoma in situ. Reported preliminary 6-month complete response rate (62%) in pivotal cohort patients enrolled under amended LEGEND protocol. enGene selected for FDA's CDRP Program to support CMC readiness. Cash and marketable securities plus proceeds from November financing expected to provide cash runway into 2H 2028. \"We are closing 2025 in a position of strength: enrollment in LEGEND's pivotal cohort is complete and the recent data update from the LEGEND pivotal cohort supports an emerging, competitive profile for the use of detalimogene as the first choice therapy in BCG-unresponsive NMIBC if approved,\" said Ron Cooper, President and Chief Executive Officer. \"With recent acceptance into FDA's CDRP program and a cash position of $342.4 million, extending our runway into the second half of 2028, we are entering the new year laser-focused on scaling our organization in prepar","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2746668461.USD","LU2237443549.SGD","LU2237443895.HKD","ENGN","BK4161","IE00BZ1G4Q59.USD","LU2237443465.HKD","BCG","TRAE","LU2237443382.USD","BK4006","LU0149725797.USD","LU0971096721.USD","LU2237443978.SGD","CR","BK4135","DDX","IE00BHPRN162.USD","BK4139","LU1363072403.SGD","R","LU2237443622.USD","LU0882574139.USD","CMC","LU0267386448.USD","LU0170899867.USD","BK4022","LU2746668974.SGD","BK4232","IE00BKVL7J92.USD","IE00BFXG1179.USD","IE00B1BXHZ80.USD"],"gpt_icon":0},{"id":"2588056337","title":"EnGene Says US FDA Selects Detalimogene for Manufacturing Pilot Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2588056337","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588056337?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:44","pubTimestamp":1764683062,"startTime":"0","endTime":"0","summary":"EnGene (ENGN) said Tuesday that the US Food and Drug Administration selected detalimogene for its chemistry, manufacturing and controls development and readiness pilot program.Detalimogene is an inves","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2588555320","title":"BRIEF-Engene’S Detalimogene Selected For FDA Manufacturing Pilot Program To Support Manufacturing Readiness","url":"https://stock-news.laohu8.com/highlight/detail?id=2588555320","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588555320?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:18","pubTimestamp":1764681501,"startTime":"0","endTime":"0","summary":"BRIEF-Engene’S Detalimogene Selected For FDA Manufacturing Pilot Program To Support Manufacturing ReadinessDec 2 (Reuters) - enGene Holdings Inc ENGN.O:ENGENE’S DETALIMOGENE SELECTED FOR FDA MANUFACTU","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X80KR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENGN"],"gpt_icon":0},{"id":"2588058033","title":"enGene Reports 62% Complete Response Rate for Detalimogene in Bladder Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2588058033","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588058033?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:47","pubTimestamp":1764679656,"startTime":"0","endTime":"0","summary":"enGene Holdings Inc. has announced positive preliminary results from the pivotal cohort of its LEGEND trial studying detalimogene voraplasmid  in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer  with carcinoma in situ  with or without concomitant papillary disease. The results showed an improved complete response rate of 62% at six months. Safety data from 125 patients demonstrated a favorable tolerability profile, with low rates of treatment-related adverse events (42%) and dose interruptions . The company has not specified if these results have already been presented at a scientific meeting or will be presented in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL4149Bc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","BK4139"],"gpt_icon":0},{"id":"2588676058","title":"enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness","url":"https://stock-news.laohu8.com/highlight/detail?id=2588676058","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588676058?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:30","pubTimestamp":1764678620,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X80KR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENGN","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.engene.com","stockEarnings":[{"period":"1week","weight":0.0684},{"period":"1month","weight":0.167},{"period":"3month","weight":0.5259},{"period":"6month","weight":1.4583},{"period":"1year","weight":0.6115},{"period":"ytd","weight":0.1761}],"compareEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":0.0102},{"period":"3month","weight":0.0386},{"period":"6month","weight":0.0607},{"period":"1year","weight":0.1167},{"period":"ytd","weight":0.0038}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.","exchange":"NASDAQ","name":"ENGENE HOLDINGS INC","nameEN":"ENGENE HOLDINGS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ENGENE HOLDINGS INC(ENGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ENGENE HOLDINGS INC(ENGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ENGENE HOLDINGS INC,ENGN,ENGENE HOLDINGS INC股票,ENGENE HOLDINGS INC股票老虎,ENGENE HOLDINGS INC股票老虎国际,ENGENE HOLDINGS INC行情,ENGENE HOLDINGS INC股票行情,ENGENE HOLDINGS INC股价,ENGENE HOLDINGS INC股市,ENGENE HOLDINGS INC股票价格,ENGENE HOLDINGS INC股票交易,ENGENE HOLDINGS INC股票购买,ENGENE HOLDINGS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ENGENE HOLDINGS INC(ENGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ENGENE HOLDINGS INC(ENGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction